Recent Updates in the Role of Bispecifics in Multiple Myeloma: Highlights from ASH 2022 and Beyond : Episode 2
Treatment Approaches in Transplant-Eligible NDMM
Sandy Wong, MD, and Alexander Lesokhin, MD, discuss how they approach the treatment of transplant-eligible NDMM using the Dara-RVd regimen.
Video Player is loading.
EP: 1.GRIFFIN Trial in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Subgroup Analysis
Now Viewing
EP: 2.Treatment Approaches in Transplant-Eligible NDMM
EP: 3.Upfront Stem Cell Transplant and Maintenance Therapy in Transplant-Eligible NDMM
EP: 4.Analysis of Patients with Transplant-Eligible NDMM with High-Risk Cytogenetic Abnormalities who Received Frontline Daratumumab-Based Quadruplet Therapy
EP: 5.Treatment Approaches in High-Risk Transplant-Eligible NDMM Based on MRD Negativity
EP: 6.Planned Interim Analysis of the GMMG-Concept Trial in High-Risk NDMM
EP: 7.Comparing Quadruplet Combination Treatment Regimens in NDMM
EP: 8.Updated Analysis of the Phase 3 MAIA Study in Transplant-Ineligible Patients with NDMM
EP: 9.Clinical Assessment of Key Subgroups of the Phase 3 Maia Study in Transplant-Ineligible Patients with NDMM
EP: 10.IFM2020-05/Benefit: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib for Elderly Patients with Transplant-Ineligible NDMM
Recent Videos
Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple Myeloma
Real World Experience of CAR-T in MM Patients
Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
Future Perspectives: What’s Next in NDMM?
Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
Jackson’s Journey with High Risk R/R MM
Role of Bridging Therapy for CAR-T Patients
Expert Perspectives: Navigating Between CEPHEUS and IMROZ Studies
Transplant-Ineligible NDMM: When to Use a Quadruplet Regimen
Related Content
